An FDA advisory committee recommended the agency allow Merck's arthritis painkiller Vioxx back on the market and permit the continued sale of other Cox-2 drugs, such as Celebrex and Bextra, but under strict conditions. While the panel favored continued sales of the drugs, the members agreed unanimously Cox-2 class drugs "significantly increase" the risk of heart attack and stroke. The panel also recommended new warnings for nonsteroidal anti-inflammatory drugs, such as Mobic and ibuprofen. The FDA is expected to announce within weeks if it will go along with the panel's recommendations.

Related Summaries